Drugs in ATC Class A07

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Subclasses in ATC: A07 - ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS

A07A - INTESTINAL ANTIINFECTIVES

A07D - ANTIPROPULSIVES

A07E - INTESTINAL ANTIINFLAMMATORY AGENTS

A07X - OTHER ANTIDIARRHEALS

Last updated: June 6, 2026

Market dynamics and patent landscape for ATC class A07 antidiarrheals, intestinal anti-inflammatory/anti-infective agents

ATC class A07 spans antidiarrheals and intestinal anti-inflammatory/anti-infective drugs, but the patent and exclusivity picture is dominated by a small set of branded, specialty, and procedure-sensitive products (oral immunomodulators/anti-inflammatories, gut-selective anti-infectives, and targeted antimicrobials). Market dynamics are shaped by (1) fast generic erosion for older antidiarrheal and broad anti-infective actives, (2) slower erosion for formulations and biologics-derived pathways where exclusivity and method-of-use patents persist, and (3) periodic FDA entry opportunities through ANDA Paragraph IV filings and, for biologics, biosimilar development.

The actionable takeaway for R&D, licensing, and litigation teams is that A07 value pools cluster where there are layered IP estates: active ingredient patents plus formulation/polymorph/process patents plus route or dosing regimen method-of-use patents, often paired with Orange Book listings that can block immediate generic switch unless the generic carves around multiple claim sets.

Which drugs define revenue and patent value inside ATC A07?

Featured snippet answer: In A07, branded revenue and patent leverage concentrate in gastrointestinal anti-inflammatory therapies and gut-acting anti-infectives with layered exclusivities, while classic antidiarrheals and older antibiotics often face earlier generic erosion.

Common A07 revenue clusters by mechanism

1. Gut-selective anti-inflammatory agents
   • Target inflammatory bowel disease (IBD) phenotypes, microscopic colitis, and inflammatory diarrhea pathways.
   • Typical IP stack: composition of matter (active), prodrug or salt forms, extended-release or site-specific release, and method-of-use for dosing regimens.
2. Intestinal anti-infective agents
   • Include gut-restricted antimicrobials and local anti-infectives where systemic exposure is limited.
   • Typical IP stack: formulation (enteric coating, granulation, sustained release), manufacturing process, and sometimes patient subpopulation indications.
3. Antidiarrheals and adsorbents
   • Often older actives with faster generic entry; patent leverage is frequently tied to specific combinations or improved release profiles.

IP stack pattern across A07

A07 patent estates usually follow one of three patterns:

• Single-branch estate: active ingredient composition patents plus a late-life formulation patent.
• Layered estate: multiple formulation/process patents and method-of-use claims that persist through multiple expiration cohorts.
• Regulatory exclusivity-driven estate: where the active ingredient patent expires but exclusivity tied to a new indication, new dosage form, or new formulation blocks generic substitution longer than expected.

What patents protect A07 antidiarrheals and intestinal anti-inflammatory/anti-infective drugs?

Featured snippet answer: A07 protection is typically composition (API), salt/prodrug/form, formulation (release control and coating), manufacturing process, and method-of-use claims for indications and dosing regimens.

Patent categories teams should map for A07

1) Composition of matter (API, salts, hydrates, polymorphs)

• Targets chemical identity, salt formation, and solid-state variants.
• Highest leverage when claim scope covers generic equivalents, not just the reference formulation.

2) Formulation patents (oral delivery engineering)

• Enteric coating, delayed release, sustained release, granulation and particle-size distributions.
• For gut targeting, courts and examiners often treat coating/particle engineering as a distinct inventive concept.

3) Method-of-use patents

• Indications and regimens: dose escalation, frequency, population stratification, and specific endpoints.
• Common where clinical data supports a narrower population and claim language is tight.

4) Manufacturing process patents

• Drying, crystallization, milling, granulation, coating conditions.
• Often used defensively to block “same API, different process” workarounds.

How many patents cover typical A07 reference products?

Featured snippet answer: Many high-value A07 reference products have multiple Orange Book-listed patents (often 5 to 20) across composition, formulation, and method-of-use. Estates at the high end usually reflect extended release or gut-targeted delivery plus new indications.

Geographic coverage considerations

• US is decisive for generic entry timing (Orange Book + 180-day exclusivity + Paragraph IV).
• EU/UK matter for parallel imports, tender specifications, and launch sequencing for generics and authorized generics.
• Japan is important for later-stage lifecycle management where patent term restoration differs.

When do A07 drugs lose exclusivity and what are the key expiration drivers?

Featured snippet answer: Exclusivity loss in A07 is governed by the later of composition and listed formulation/method-of-use patent expirations, with regulatory exclusivity and patent term adjustments acting as swing factors for US ANDA timing.

US timeline mechanics that matter

1. Orange Book-listed patent expirations
   • For ANDAs, the generic must certify to each listed patent or carve out with a Paragraph IV strategy.
2. Regulatory exclusivity overlays
   • New chemical entity (NCE) exclusivity and new clinical investigation exclusivity can extend brand protection even after earlier patent expirations.
3. Patent term adjustment (PTA)
   • Can add years for patents affected by USPTO delay, shifting launch windows.

What typically extends protection in A07?

• Formulation with delivery control (delayed/released delivery tied to claims).
• New indication or subpopulation claims captured as method-of-use.
• Late-filing continuation strategy creating overlapping expiration cohorts.

What patent expirations drive generic launch risk in A07?

Featured snippet answer: Generic launch risk is highest when (1) fewer patents remain Orange Book-listed for the reference drug’s specific dosage form, and (2) method-of-use and formulation claims lapse earlier than the composition patent or are easier to design around.

Launch risk map

• Low risk: multiple independent claim families still in force (composition + formulation + method-of-use).
• Medium risk: composition patents expired or weak, but formulation/method-of-use remain.
• High risk: only a narrow formulation or dosing regimen patent set remains, with claim scope that allows workarounds.

Which A07 companies are challenging patents via Paragraph IV ANDAs?

Featured snippet answer: Paragraph IV activity inside A07 tends to concentrate among large generic firms and aggressive Paragraph IV specialists that target branded oral therapies with layered formulation and method-of-use estates.

Typical challenger behavior

• File ANDA with “4” certification against one or more Orange Book patents.
• Bet on a combination of claim invalidation and non-infringement by:
  • shifting formulation parameters,
  • modifying release profile or coating,
  • altering method-of-use label representation.

What is the Orange Book status of A07 drugs and how does it affect FDA approval timing?

Featured snippet answer: Orange Book lists patents that gate generic certifications; A07 brand protection relies on how many patents cover each dosage form and how late those patents expire.

Orange Book mapping approach for A07

• Identify all listed patents by:
  • patent number,
  • claim type (composition/formulation/method-of-use),
  • expiration dates,
  • whether they are tied to specific strengths or dosage forms.
• Use that mapping to:
  • compute earliest “certify-to-expiration” date,
  • evaluate whether a Paragraph IV carve-out would be needed for meaningful commercial entry.

How strong is the patent estate for A07 anti-inflammatory and anti-infective products?

Featured snippet answer: Estate strength in A07 is highest where:

• claims are layered across multiple independent patent families,
• at least one family is method-of-use or formulation with narrow but enforceable delivery parameters,
• litigation history shows courts have treated the claims as non-trivially distinct.

Signals of enforceability

• Multiple continuation filings that preserve claim coverage through lifecycle.
• Drafting that ties structure-to-function for release and dosing.
• Presence of process patents that complicate “drop-in replacement” manufacturing.

Signals of vulnerability

• Claims drafted broadly to cover functional equivalents without specific parameters.
• Early invalidation in prior cases for the same claim family.
• Regulatory labeling constraints that prevent meaningful “carve-out” strategies.

What formulation patents in A07 matter for generic design-around?

Featured snippet answer: For A07 gut-targeted oral therapies, the highest design-around friction is delayed-release, enteric-coating, particle-size distribution, and sustained-release mechanism claims.

Design-around vectors generics use

• Reformulate coating thickness or polymer selection to change dissolution profile.
• Adjust granulation to shift release kinetics.
• Switch manufacturing route while preserving comparable bioavailability.

Enforcement pressure points

• Claims that recite quantitative dissolution targets or coating parameters.
• Process patents that specify temperature/time/solvent regimes or crystallization endpoints.

What method-of-use patents in A07 affect label and switching?

Featured snippet answer: Method-of-use patents typically restrict label alignment, forcing generics to omit certain indications or dosing regimens, which can slow uptake or require separate commercial strategies.

Typical method-of-use claim targets

• Indication-specific claims:
  • disease stage or phenotype,
  • prior therapy failure,
  • severity threshold.
• Dosing regimen claims:
  • induction vs maintenance windows,
  • titration schedules,
  • frequency adjustments.

What patent litigation affects A07 generics and biosimilars?

Featured snippet answer: A07 litigation affecting generic entry usually centers on ANDA Paragraph IV disputes over Orange Book-listed patents, with biologics-related activity occurring when A07 includes anti-inflammatory biologic pathways.

Litigation outcomes that change market entry

• Injunctions that delay launch dates beyond statutory “t” certification timelines.
• Settlements that convert a “4” challenge into delayed commercial entry with agreed launch dates and sometimes design changes.
• Court decisions narrowing claim scope, enabling faster than expected entry.

When do settlements and consent judgments change A07 launch timelines?

Featured snippet answer: Settlements typically shift generic entry to a later date than the earliest “patent expiration” if the parties agree to trigger conditions like dismissal or non-launch periods.

Common settlement terms in A07 (transactional patterns)

• Agreed “trigger” date for launch.
• License terms for certain patents or formulations.
• Dismissal of litigation with standstill on certain product representations.

What is the biosimilar risk in A07 for intestinal anti-inflammatory therapies?

Featured snippet answer: Biosimilar risk is highest when:

• originator biologics have expiring reference product exclusivities,
• manufacturing and formulation patents lapse earlier than method-of-use claims, and
• court or settlement outcomes remove injunction barriers.

Biosimilar gating factors

• Patent landscape around:
  • formulation buffers and lyophilization cycles,
  • device/container systems,
  • method-of-use by indication and dosage schedule.
• Labeling strategy: biosimilars often need label comparability, which can be constrained by active patents tied to specific indications.

How does A07 market competition differ between antidiarrheals and intestinal anti-inflammatory/anti-infective drugs?

Featured snippet answer: Antidiarrheals face faster generic saturation; intestinal anti-inflammatories/anti-infectives face slower erosion when IP estates are anchored in delivery/formulation and method-of-use.

Competitive structure

• Antidiarrheals: pricing pressure and multiple generic SKUs; patents often limited to combinations and specific formulations.
• Anti-inflammatory/anti-infective: fewer SKUs, higher brand retention when IP estates persist; higher switching costs driven by clinical practice and dosing specificity.

Which A07 dosage forms create the biggest patent and regulatory barriers?

Featured snippet answer: Oral controlled-release, delayed-release, and gut-targeted formulations create the biggest barriers due to enforceable formulation and manufacturing patents and because generic label substitution can be slower.

Dosage-form-specific IP

• Capsules/tablets with enteric coating:
  • more formulation claim coverage,
  • more dissolution profile evidence.
• Granules/sachets/suspensions:
  • process and particle-size claims,
  • stability and shelf-life claims.
• Systemic anti-inflammatory therapies (where applicable in A07):
  • method-of-use and device/container patents.

What generic entry risks exist for A07 gut-targeted oral therapies?

Featured snippet answer: The biggest risks for generic entrants are multi-patent infringement exposure and inability to achieve a non-infringing dissolution/release profile without changing bioequivalence.

Entry-risk matrix

• Non-infringement difficulty: claims tied to quantitative dissolution or coating parameters.
• Invalidity burden: overlapping claim families created via continuation.
• Regulatory timing: even if a patent is challenged, an injunction or settlement can delay approval to a later date.

What commercial impact do patent expirations have on A07 revenue exposure?

Featured snippet answer: A07 revenue exposure concentrates in products with at least one active Orange Book-listed formulation or method-of-use patent family close to expiration. When those patents expire or are carved out, revenue compression accelerates due to fast generic uptake.

Revenue sensitivity logic

• Products with single-patent remaining tend to see earlier generic switching.
• Products with layered formulation and method-of-use typically remain protected longer, reducing immediate revenue erosion.

Key Takeaways

• A07 exclusivity and patent leverage are concentrated in gut-targeted anti-inflammatory and anti-infective therapies where formulation and method-of-use claims extend the IP estate beyond basic composition patents.
• Generic entry risk is driven less by API identity and more by Orange Book-listed formulation and dosing regimen patents for specific dosage forms.
• Paragraph IV and settlement dynamics can move launch dates materially even when patents are near expiry, creating timing uncertainty that must be modeled by claim-family and dosage form.
• Market competition diverges sharply inside A07: classic antidiarrheals saturate faster; controlled-release and gut-targeted products maintain stronger brand retention when layered patents persist.

FAQs

1. How do Orange Book patent claim types (composition vs formulation vs method-of-use) change ANDA strategy for A07 drugs?
2. Which A07 patent families are most frequently targeted in Paragraph IV certifications: formulation, process, or method-of-use?
3. How do dissolution and release-profile differences affect non-infringement arguments for gut-targeted A07 oral products?
4. What settlement structures most commonly delay A07 generic launches after a successful Paragraph IV filing?
5. When A07 involves biologics for intestinal inflammation, what patent buckets most constrain biosimilar label and launch timing?

References

1. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration.
2. FDA. Drug Products (Approved Drug Products). U.S. Food and Drug Administration.
3. U.S. Patent and Trademark Office (USPTO). Patent term adjustment and patent term concepts. USPTO.